Dermapharm Holding SE (DMP.F)
- Previous Close
30.95 - Open
31.00 - Bid 31.20 x --
- Ask 31.85 x --
- Day's Range
31.00 - 31.65 - 52 Week Range
30.95 - 49.16 - Volume
120 - Avg. Volume
152 - Market Cap (intraday)
1.704B - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
27.28 - EPS (TTM)
1.16 - Earnings Date May 15, 2024
- Forward Dividend & Yield 0.88 (2.78%)
- Ex-Dividend Date Jun 6, 2024
- 1y Target Est
31.50
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products. It offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. The company also provides medical devices under the bite away and Herpotherm names. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-AG.
ir.dermapharm.de3,497
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DMP.F
Performance Overview: DMP.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMP.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMP.F
Valuation Measures
Market Cap
1.70B
Enterprise Value
2.62B
Trailing P/E
27.28
Forward P/E
16.34
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.50
Price/Book (mrq)
3.16
Enterprise Value/Revenue
2.31
Enterprise Value/EBITDA
9.88
Financial Highlights
Profitability and Income Statement
Profit Margin
5.42%
Return on Assets (ttm)
6.76%
Return on Equity (ttm)
11.24%
Revenue (ttm)
1.15B
Net Income Avi to Common (ttm)
62.37M
Diluted EPS (ttm)
1.16
Balance Sheet and Cash Flow
Total Cash (mrq)
159.54M
Total Debt/Equity (mrq)
198.22%
Levered Free Cash Flow (ttm)
106.43M
Research Analysis: DMP.F
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: DMP.F
DMP.F does not have Company Insights